[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ahmed Saad\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":50},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":5},"100649613","phase-1-drospirenone-primed-ovarian-stimulation-versus-gnrh-antagonist-protocol-in-poor-ovarian-responders-undergoing-freeze-all-ivficsi-100649613",false,"NCT07736261","Drospirenone-Primed Ovarian Stimulation Versus GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing Freeze-All IVF\u002FICSI","Drospirenone-Primed Ovarian Stimulation (PPOS) Versus Flexible GnRH Antagonist Protocol in Poor Ovarian Responders Undergoing a Freeze-All Strategy: A Pilot Randomized Controlled Trial","PPOS","Inclusion Criteria:\n\n* Spontaneous menstrual cycles (21-35 days)\n* Poor ovarian response per Bologna criteria (≥2 of 3): advanced age ≥40 or risk factor for POR; previous poor response (≤3 oocytes with conventional stimulation); abnormal ovarian reserve (AFC \\\u003C7 or AMH \\\u003C1.1 ng\u002FmL)\n* POSEIDON group recorded at enrollment (1-4) for stratified randomization and pre-specified subgroup description - corrects a known limitation of Bologna-only classification, which pools biologically distinct POR phenotypes\n* Indication for IVF\u002FICSI\n* Willing and able to undergo mandatory freeze-all\u002FFET protocol\n* Signed informed consent, including explicit acknowledgment that fresh transfer is not offered in either study arm\n\nExclusion Criteria:\n\n* Contraindication to ovarian stimulation\n* Known müllerian anomaly\n* Uncontrolled systemic disease\n* 5 prior failed IVF attempts\n* Known contraindication to drospirenone (per product labeling, e.g., renal impairment, adrenal insufficiency, conditions predisposing to hyperkalemia)","FEMALE","20 Years","42 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","Participants will:\n\n* Take either drospirenone (a daily pill) or the standard daily injection during their ovarian stimulation cycle, alongside their regular fertility hormone injections\n* Undergo egg retrieval, with all resulting embryos frozen (no fresh embryo transfer in this study)\n* Have a frozen embryo transferred in a later cycle\n* Complete two short questionnaires about their treatment experience - once before starting the injections\u002Fpills, and once after the stimulation phase ends\n* Be followed to determine if the embryo transfer results in a pregnancy",[29,30],"Poor Ovarian Reserve","Infertility (IVF Patients)",[32,33,34,35,36,37],"poor ovarian response","diminished ovarian reserve","Drospirenone","progestin primed ovarian stimulation","GnRH antagonist","Freeze all","NOT_YET_RECRUITING","2026-07-29",{"date":41,"type":42},"2026-07-30","ACTUAL",{"date":44,"type":22},"2026-08",{"date":46,"type":22},"2027-11",{"name":48,"class":49},"Ahmed Saad","OTHER",""]